ABC NAMES EXECUTIVE DIRECTORThe Association of Biotechnology Companies in Washington,D.C., has named William E. Small executive director. Small wasexecutive director of the National Foundation for InfectiousDiseases.
Thomas L. Churchwell has been appointed chief executiveofficer of Calgene Fresh Inc., a new subsidiary of Calgene Inc.He had been vice president of ARCH Development Corp., aventure capital firm. Calgene (NASDAQ:CGNE) of Davis, Calif., isdeveloping improved plant varieties and products for the seed,food and specialty chemical business.
Greg D. Phelps has been named president of Neozyme Corp. andsenior vice president of corporate development of GenzymeCorp., both of Cambridge, Mass. Phelps was president and chiefexecutive officer of Viagene Inc. Neozyme is an R&D spinoff ofGenzyme.
TheraTech Inc. of Salt Lake City has named Steven C. Mayervice president and chief financial officer. Mayer was vicepresident and CFO at NPI, an agricultural biotechnologycompany. TheraTech develops products based on controlled-release drug delivery technologies.
Cor Therapeutics Inc. has appointed Laura A. Brege vicepresident of finance and chief financial officer. She replaces R.Lee Douglas Jr., who will continue as vice president of corporatedevelopment. Brege was vice president of finance and CFO ofComputer Aided Service Inc. Cor (NASDAQ:CORR) of South SanFrancisco, Calif., is focused on acute cardiovascular diseases.
Chiron Corp. (NASDAQ:CHIR) of Emeryville, Calif., has electedGilbert F. Amelio and Jack W. Schuler to its board.. Amelio ispresident and chief executive officer of National SemiconductorCorp. Schuler was president and chief operating officer forAbbott Laboratories from 1987 to 1989.
Sugen Inc., a Redwood City, Calif., company focused on cellsurface receptor technology, has named to its board CharlesHartman of CW Group; Michael Wall, a founder and director ofCentocor Inc. and Alkermes Inc.; and Glenn Utt, a director ofSynergen Inc. and former president of Abbott LaboratoriesPharmaceutical Products Division. Anthony Evnin of VenrockAssociates is expected to join the board later this year, Sugensaid.
(c) 1997 American Health Consultants. All rights reserved.